By Ben James

Law360, New York (November 02, 2009, 1:04 PM ET) -- Solvay Pharmaceuticals Inc. has asked a judge to dismiss three indirect purchaser cases from the multidistrict litigation over allegedly anti-competitive patent litigation pacts related to the drug AndroGel, arguing that the settlements allow for generic competition years before the AndroGel patent expires.

Solvay and Watson Pharmaceuticals Inc. filed their motion to dismiss the three indirect purchaser suits in the U.S. District Court for the Northern District of Georgia on Friday.

Also on Friday, Solvay and Watson's fellow defendants Par Pharmaceutical Cos. Inc. and Paddock Laboratories Inc....